Amgen's ‘Neulasta’ market enters into competition system
Amgen's mega blockbuster biopharmaceutical Neulasta (neutropenia treatment) market enters into competition system, because domestic top pharmaceutical companies also received final approval of biobetter recently.
Representative neutropenia treatment 'Neulasta' is for the treatment of febrile neu...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
